Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas

Study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B-cell lymphomas.